Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-06

Clinical Trial Update: Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896) [Phase 3]

View source ↗

Summary

Phase 3 fixed-dose efficacy and safety trial of asenapine for schizophrenia in adolescents has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Saphris (asenapine)

Snippet

Sponsor: Organon and Co | Conditions: Schizophrenia, Paranoid, Schizophrenia, Disorganized | Phase 3 | Status: COMPLETED | Results posted: 2014-06-06